FTDZX — Franklin Biotechnology Discovery Fund
Data updated: 2026-08-25
FTDZX — Franklin Biotechnology Discovery Fund. United States Multi-Cap / All-Cap Growth Health Care Equity. Holdings, fees, performance and SEC filings.
FTDZX Fund Overview
FTDZX — Franklin Biotechnology Discovery Fund is a US mutual fund managed by Franklin Strategic Series, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Franklin Strategic Series
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $1.04B
- 1-year return: 65.4%
- Ticker: FTDZX
- SEC CIK: 0000872625
- SEC series ID: S000006882
- Share class ID: C000081539
FTDZX Holdings
Top 10 holdings of Franklin Biotechnology Discovery Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Jazz Pharmaceuticals plc | 5.55% |
| Amgen, Inc. | 4.75% |
| Gilead Sciences, Inc. | 4.66% |
| Regeneron Pharmaceuticals, Inc. | 4.16% |
| Vertex Pharmaceuticals, Inc. | 4.02% |
| Argenx SE | 3.69% |
| Franklin Institutional U.S. Government Money Market Fund | 3.05% |
| Franklin Institutional U.S. Government Money Market Fund | 2.96% |
| Ascendis Pharma A/S | 2.87% |
| Insmed, Inc. | 2.82% |
FTDZX Portfolio Allocation
Asset-class allocation of Franklin Biotechnology Discovery Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.7% |
| Cash & Equivalents | 6.0% |
| Other | 0.5% |
FTDZX Performance
Total returns for FTDZX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.7% |
| 1 year | 65.4% |
| 3 years (annualised) | 23.5% |
| 5 years (annualised) | 8.4% |
FTDZX Risk Information
Risk metrics for FTDZX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 19.4%
FTDZX Costs and Fees
FTDZX costs about $76 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.76%
- Gross expense ratio: 0.77%
- Portfolio turnover: 38%
- Brokerage commissions: 8.31 bps of average net assets (SEC N-CEN)
FTDZX Cashflows
Over the 12 months to 2026-04, Franklin Biotechnology Discovery Fund had net outflows of $463.48K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$5.06M |
| 2026-03 | −$7.95M |
| 2026-02 | −$13.78M |
| 2026-01 | −$7.25M |
| 2025-12 | $81.00M |
| 2025-11 | $2.90M |
FTDZX Debt Constituents
No individual debt constituents are reported in Franklin Biotechnology Discovery Fund's latest SEC N-PORT filing.
FTDZX Prospectus and SEC Filings
Official Franklin Biotechnology Discovery Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-08-25
- Prospectus (485BPOS) — filed 2025-08-26
- Prospectus (485BPOS) — filed 2024-08-26
- Portfolio holdings (N-PORT) — filed 2026-06-24
- Portfolio holdings (N-PORT) — filed 2026-03-27
- Portfolio holdings (N-PORT) — filed 2025-12-23
- Annual census (N-CEN) — filed 2026-07-10
- Annual census (N-CEN) — filed 2025-07-11
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.